share_log

百利天恒(688506.SH)：BL-B01D1单药治疗非小细胞肺癌的III期临床试验完成首例受试者入组

Baili Tianheng (688506.SH): Phase III clinical trial of BL-B01D1 monotherapy for non-small cell lung cancer completed the first patient enrollment

Zhitong Finance ·  May 29 19:43

Baili Tianheng (688506.SH) announced that the company's self-developed innovative biopharmaceutical injectable BL-B01D1...

Zhitong Finance App News, Bailey Tianheng (688506.SH) announced that the phase III clinical trial of the innovative biopharmaceutical BL-B01D1 (EGFR×HER3-ADC) monotherapy developed independently by the company for locally advanced or metastatic non-small cell lung cancer with EGFR-sensitive mutations that failed EGFR-TKI treatment has recently completed the enrollment of the first test subjects.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment